IM Cannabis Corp. (IMCC)
USD 2.11
(-8.26%)
USD 2.11
(-8.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 48.81 Million CAD | -19.55% |
| 2022 | 60.67 Million CAD | -78.89% |
| 2021 | 287.38 Million USD | 653.98% |
| 2020 | 38.11 Million CAD | 23.38% |
| 2019 | 30.89 Million CAD | 83390.53% |
| 2018 | 37 Thousand CAD | 304.71% |
| 2017 | 9143.00 CAD | 3212.68% |
| 2016 | 276.00 CAD | 0.0% |
| 2015 | 276.00 CAD | -98.29% |
| 2014 | 16.1 Thousand CAD | -43.96% |
| 2013 | 28.73 Thousand CAD | -68.83% |
| 2012 | 92.16 Thousand CAD | -99.05% |
| 2011 | 9.7 Million CAD | 0.21% |
| 2010 | 9.68 Million CAD | -1.36% |
| 2009 | 9.82 Million CAD | 53.28% |
| 2008 | 6.4 Million CAD | 124.93% |
| 2007 | 2.84 Million CAD | 70.18% |
| 2006 | 1.67 Million CAD | 51.89% |
| 2005 | 1.1 Million CAD | -4.01% |
| 2004 | 1.14 Million CAD | 30.21% |
| 2003 | 881.91 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 40.21 Million CAD | -2.17% |
| 2024 Q1 | 41.1 Million CAD | -15.78% |
| 2023 Q1 | 56.79 Million USD | -6.4% |
| 2023 Q2 | 55.75 Million CAD | -1.83% |
| 2023 Q4 | 48.81 Million CAD | -6.78% |
| 2023 FY | 48.81 Million CAD | -19.55% |
| 2023 Q3 | 52.36 Million CAD | -6.07% |
| 2022 Q2 | 255.3 Million CAD | -9.17% |
| 2022 Q3 | 129.06 Million CAD | -49.45% |
| 2022 Q1 | 281.06 Million CAD | -2.2% |
| 2022 Q4 | 60.67 Million CAD | -52.99% |
| 2022 FY | 60.67 Million CAD | -78.89% |
| 2021 Q2 | 200.03 Million CAD | 20.32% |
| 2021 Q1 | 166.25 Million CAD | 336.17% |
| 2021 Q3 | 275.38 Million CAD | 37.67% |
| 2021 Q4 | 287.38 Million USD | 4.36% |
| 2021 FY | 287.38 Million USD | 653.98% |
| 2020 Q2 | 39.15 Million CAD | 12.71% |
| 2020 Q4 | 38.11 Million CAD | -4.01% |
| 2020 Q3 | 39.71 Million CAD | 1.43% |
| 2020 Q1 | 34.73 Million CAD | 12.44% |
| 2020 FY | 38.11 Million CAD | 23.38% |
| 2019 Q1 | 37 Thousand CAD | 28.0% |
| 2019 FY | 30.89 Million CAD | 83390.53% |
| 2019 Q2 | 41.11 Thousand CAD | 11.1% |
| 2019 Q3 | 15.19 Million CAD | 36855.15% |
| 2019 Q4 | 30.89 Million CAD | 103.34% |
| 2018 Q1 | 9143.00 CAD | -26.77% |
| 2018 FY | 37 Thousand CAD | 304.71% |
| 2018 Q4 | 28.9 Thousand CAD | 0.0% |
| 2017 Q2 | 276.00 CAD | 0.0% |
| 2017 Q4 | 12.48 Thousand CAD | -48.33% |
| 2017 Q3 | 24.16 Thousand CAD | 8653.99% |
| 2017 Q1 | 276.00 CAD | 0.0% |
| 2017 FY | 9143.00 CAD | 3212.68% |
| 2016 FY | 276.00 CAD | 0.0% |
| 2015 FY | 276.00 CAD | -98.29% |
| 2014 Q3 | 26.33 Thousand CAD | -47.57% |
| 2014 FY | 16.1 Thousand CAD | -43.96% |
| 2014 Q1 | 28.73 Thousand CAD | 0.74% |
| 2014 Q4 | 27.97 Thousand CAD | 6.21% |
| 2014 Q2 | 50.23 Thousand CAD | 74.84% |
| 2013 FY | 28.73 Thousand CAD | -68.83% |
| 2013 Q4 | 28.51 Thousand CAD | -17.21% |
| 2013 Q3 | 34.44 Thousand CAD | -59.35% |
| 2013 Q2 | 84.74 Thousand CAD | -8.05% |
| 2013 Q1 | 92.16 Thousand CAD | -99.08% |
| 2012 FY | 92.16 Thousand CAD | -99.05% |
| 2012 Q1 | 9.7 Million CAD | 1.2% |
| 2012 Q3 | 10.01 Million CAD | -0.49% |
| 2012 Q4 | 10.06 Million CAD | 0.5% |
| 2012 Q2 | 10.06 Million CAD | 3.68% |
| 2011 Q2 | 9.64 Million CAD | -0.49% |
| 2011 Q4 | 9.59 Million CAD | 1.07% |
| 2011 FY | 9.7 Million CAD | 0.21% |
| 2011 Q1 | 9.68 Million CAD | 2.57% |
| 2011 Q3 | 9.49 Million CAD | -1.54% |
| 2010 Q1 | 9.82 Million CAD | 5.99% |
| 2010 Q2 | 9.72 Million CAD | -0.96% |
| 2010 Q3 | 9.56 Million CAD | -1.68% |
| 2010 FY | 9.68 Million CAD | -1.36% |
| 2010 Q4 | 9.44 Million CAD | -1.25% |
| 2009 Q4 | 9.26 Million CAD | 50.04% |
| 2009 Q3 | 6.17 Million CAD | -1.83% |
| 2009 FY | 9.82 Million CAD | 53.28% |
| 2009 Q2 | 6.29 Million CAD | -1.83% |
| 2009 Q1 | 6.4 Million CAD | 10.92% |
| 2008 FY | 6.4 Million CAD | 124.93% |
| 2008 Q4 | 5.77 Million CAD | -2.82% |
| 2008 Q3 | 5.94 Million CAD | -0.26% |
| 2008 Q2 | 5.96 Million CAD | 109.22% |
| 2008 Q1 | 2.84 Million CAD | 19.65% |
| 2007 Q1 | 1.67 Million CAD | 104.17% |
| 2007 Q3 | 1.46 Million CAD | -12.6% |
| 2007 Q2 | 1.67 Million CAD | 0.07% |
| 2007 FY | 2.84 Million CAD | 70.18% |
| 2007 Q4 | 2.38 Million CAD | 62.62% |
| 2006 Q4 | 820.02 Thousand CAD | -17.98% |
| 2006 FY | 1.67 Million CAD | 51.89% |
| 2006 Q2 | 1.05 Million CAD | -4.66% |
| 2006 Q1 | 1.1 Million CAD | 37.5% |
| 2006 Q3 | 999.79 Thousand CAD | -4.87% |
| 2005 Q4 | 801.66 Thousand CAD | -36.58% |
| 2005 FY | 1.1 Million CAD | -4.01% |
| 2005 Q1 | 1.14 Million CAD | 3.57% |
| 2005 Q3 | 1.26 Million CAD | 2.31% |
| 2005 Q2 | 1.23 Million CAD | 7.6% |
| 2004 Q3 | 1.18 Million CAD | 44.91% |
| 2004 Q4 | 1.1 Million CAD | -6.08% |
| 2004 Q1 | 881.91 Thousand CAD | -3.83% |
| 2004 FY | 1.14 Million CAD | 30.21% |
| 2004 Q2 | 814.65 Thousand CAD | -7.63% |
| 2003 Q3 | 1.56 Million CAD | 201.04% |
| 2003 Q2 | 519.05 Thousand CAD | 0.0% |
| 2003 FY | 881.91 Thousand CAD | 0.0% |
| 2003 Q4 | 916.99 Thousand CAD | -41.31% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Theratechnologies Inc. | 77.76 Million USD | 37.233% |
| Harrow Health, Inc. | 311.75 Million USD | 84.343% |
| Dynavax Technologies Corporation | 997.09 Million USD | 95.104% |
| Biofrontera Inc. | 27.93 Million USD | -74.757% |
| Cronos Group Inc. | 1.13 Billion USD | 95.696% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -227.758% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 89.638% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 12.754% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -111.796% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 40.309% |
| Radius Health, Inc. | 1.71 Billion USD | 97.155% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 8.396% |
| DURECT Corporation | 45.18 Million USD | -8.02% |
| ProPhase Labs, Inc. | 91.92 Million USD | 46.9% |
| Safety Shot Inc | 12.7 Million USD | -284.077% |
| Phibro Animal Health Corporation | 982.18 Million USD | 95.03% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -111.064% |
| Alvotech | 950.09 Million USD | 94.862% |
| Assertio Holdings, Inc. | 286.41 Million USD | 82.957% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 96.536% |
| Rockwell Medical, Inc. | 52.17 Million USD | 6.44% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -78.495% |
| Procaps Group S.A. | 460.18 Million USD | 89.393% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 93.298% |
| SCYNEXIS, Inc. | 128.41 Million USD | 61.987% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 58.666% |
| Viatris Inc. | 47.68 Billion USD | 99.898% |
| OptiNose, Inc. | 107.72 Million USD | 54.689% |
| SIGA Technologies, Inc. | 254.83 Million USD | 80.845% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.874% |
| PetIQ, Inc. | 868.22 Million USD | 94.378% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -78.495% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.499% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -309.568% |
| Alimera Sciences, Inc. | 153.52 Million USD | 68.205% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 95.731% |
| Silver Spike Investment Corp. | 88.57 Million USD | 44.892% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -720.147% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 89.389% |
| Journey Medical Corporation | 76.84 Million USD | 36.482% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -44.435% |
| Alpha Teknova, Inc. | 128.58 Million USD | 62.039% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -56.237% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 82.166% |
| PainReform Ltd. | 9.93 Million USD | -391.571% |
| Cosmos Health Inc. | 66.29 Million USD | 26.371% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 81.307% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -12.709% |
| Embecta Corp. | 1.21 Billion USD | 95.98% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -478.476% |
| Talphera, Inc. | 20.39 Million USD | -139.338% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 96.9% |
| Incannex Healthcare Limited | 17.04 Million USD | -186.344% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -268.468% |
| Shineco, Inc. | 84.17 Million USD | 42.013% |
| Procaps Group, S.A. | 460.18 Million USD | 89.393% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 94.603% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 14.987% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 97.044% |
| Alvotech | 950.09 Million USD | 94.862% |
| Hempacco Co., Inc. | 18.04 Million USD | -170.536% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 87.982% |
| Bright Green Corporation | 17.4 Million USD | -180.485% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 76.281% |
| Kamada Ltd. | 351.96 Million USD | 86.131% |
| Indivior PLC | 1.95 Billion USD | 97.498% |
| Evoke Pharma, Inc. | 7.06 Million USD | -590.566% |
| Flora Growth Corp. | 23.62 Million USD | -106.607% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -268.468% |
| Evolus, Inc. | 188.99 Million USD | 74.173% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 96.186% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 96.774% |
| Akanda Corp. | 8.83 Million USD | -452.184% |